Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1

Thymidine kinases have an important role in the synthesis of DNA and exhibit high activity in rapidly proliferating cells. Thymidine kinase 1 (TK1) activity has been shown to be increased in various cancer types and proposed as a prognostic parameter.

Aim of the present study was to investigate TK1 in muscle-invasive urothelial carcinoma (UC).

Corresponding UC and benign samples from paraffin embedded tissue of 111 patients treated with cystectomy for invasive UC from 1996 to 2006 were immunohistochemically (IHC) assessed for TK1. IHC expression patterns were evaluated in a semiquantitative fashion by 2 independent reviewers. Localization of staining was categorized into pure nuclear and additional cytoplasmic localization. Uni- and multivariate analyses were performed to assess differential expression in normal and UC tissue and to evaluate the diagnostic and predictive capability of TK1 by correlation to clinical data. To correlate TK1 expression with molecular subtypes of UC, analysis of TK1 RNA expression levels of the Cancer Genome Atlas UC cohort was performed.

TK1 was significantly overexpressed in invasive UC, compared to benign urothelium (P

TK1 expression is significantly different in invasive UC and benign urothelium, which underlines its potential as a diagnostic marker. Although TK1 is considered to be a marker of proliferation, and TK1 RNA overexpression is associated with an aggressive UC subtype, its capability as a predictive IHC biomarker for invasive UC remains limited.

Urologic oncology. 2015 Jul 29 [Epub ahead of print]

Steffen Rausch, Joerg Hennenlotter, Katharina Teepe, Ursula Kuehs, Stefan Aufderklamm, Simone Bier, Johannes Mischinger, Georgios Gakis, Arnulf Stenzl, Christian Schwentner, Tilman Todenhöfer

Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany. , Department of Urology, University Hospital, Eberhard-Karls-University, Tuebingen, Germany; Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.  

PubMed